Overview
- Three plaintiff firms issued investor notices on September 28, 2026 inviting shareholders to join securities lawsuits and warning of a November 3, 2026 deadline to seek lead‑plaintiff status.
- The complaints allege Beta Bionics concealed or downplayed an FDA Form 483 and thousands of consumer reports about the iLet automated insulin delivery system, including alleged life‑threatening hypoglycemic events.
- One filing cites an asserted figure of over 18,000 complaints and claims the company failed to investigate or properly report serious incidents to the FDA.
- Plaintiffs say company statements that remediation was advanced and FDA issues were 'very benign' were misleading, but no class has been certified and the allegations remain unproven.
- If the lawsuits advance, they could prompt intense discovery, potential regulatory follow‑up and market consequences for shareholders, with key next steps including lead‑plaintiff motions and possible class certification.